Little Green Pharma (ASX:LGP) Debt-to-EBITDA : -1.62 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Little Green Pharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Little Green Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was A$2.72 Mil. Little Green Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was A$3.05 Mil. Little Green Pharma's annualized EBITDA for the quarter that ended in Sep. 2023 was A$-3.56 Mil. Little Green Pharma's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -1.62.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Little Green Pharma's Debt-to-EBITDA or its related term are showing as below:

ASX:LGP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.24 Med: -0.19 Max: 0.06
Current: -3.24

During the past 4 years, the highest Debt-to-EBITDA Ratio of Little Green Pharma was 0.06. The lowest was -3.24. And the median was -0.19.

ASX:LGP's Debt-to-EBITDA is ranked worse than
100% of 659 companies
in the Drug Manufacturers industry
Industry Median: 1.7 vs ASX:LGP: -3.24

Little Green Pharma Debt-to-EBITDA Historical Data

The historical data trend for Little Green Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Little Green Pharma Debt-to-EBITDA Chart

Little Green Pharma Annual Data

Trend

Jun19

Jun20

Jun21

Mar23

Debt-to-EBITDA

N/A

-0.19

0.06

-2.59

Little Green Pharma Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Mar23	Sep23
Debt-to-EBITDA	Get a 7-Day Free Trial			1.52	0.03	-0.74	N/A	-1.62

Competitive Comparison of Little Green Pharma's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Little Green Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Little Green Pharma's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Little Green Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Little Green Pharma's Debt-to-EBITDA falls into.

Little Green Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Little Green Pharma's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(6.556	+	5.312)	/	-4.577
	=	-2.59

Little Green Pharma's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(2.721	+	3.046)	/	-3.556
	=	-1.62

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Sep. 2023) EBITDA data.

Little Green Pharma (ASX:LGP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Little Green Pharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Little Green Pharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Little Green Pharma (ASX:LGP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Little Green Pharma Ltd (ASX:LGP) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

66 Kings Park Road, Level 2, Suite 2, West Perth, Perth, WA, AUS, 6005

Website

https://www.littlegreenpharma.com

Little Green Pharma Ltd is engaged in the vertically integrated medicinal cannabis business. The business activities of the company include cultivation, production, research and development, manufacturing, and distribution of medicinal cannabis products. The company's two key types of products available at Little Green Pharma are oils (which are ingested) and flowers (which are usually inhaled through vaporizing). The company offers LGP-branded medicinal cannabis oil products in the Australian and European markets.

Little Green Pharma (ASX:LGP) Headlines

No Headlines